Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems

Figures & data

Figure 1. Illustration depicts multidrug resistance (MDR) mechanisms in cancer cells. Enhanced drug efflux, expression of MDR proteins, reduced drug uptake, poor drug target interaction and deregulated apoptosis are some of the important mechanisms.

Figure 2. Nanoparticle-based co-delivery of siRNA and chemotherapeutic drug overcomes MDR by siRNA-mediated p-glycoprotein (p-gp) suppression. Increased drug accumulation in cells triggers apoptosis mechanisms.

Table 1. Co-delivery of miRNA, miRNA inhibitor or plasmid DNA with other cancer therapeutic agents via nanoparticles.

Nanoparticles	miRNA/pDNA/inhibitor	Co-delivered therapeutics	Target cancer	References
Methoxy poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylenecarbonate-graft-dodecanol-graft-tetraethylene-pentamine): micelle	miR-let7B	GDC-0449-Hedgehog signaling inhibitor	Pancreatic ductal adenocarcinoma	^103
GC4 svFv-liposome-polycation-hyaluronic acid (LPH) nanoparticle	miR-34a	siRNAs (c-Myc, MDM2, VEGF)	Lung metastasis of murine B16F10 melanoma	^104
Chitosan-coated polylactic acid nanoparticle	Proteasome Beta subunit 5 (β5) pDNA	Cisplatin, P62 siRNA	Ovarian cancer cells	^24
Mesoporous silica nanoparticle	Model single strand DNA (ssDNA)	Doxorubicin	HeLa cells	^105
PAMAM modified NIR-responsive hollow gold nanoparticle	miR-21 inhibitor	Doxorubicin	Breast cancer cells and breast cancer stem cells.	^106
Hyaluronic acid-coated PEI-PLGA nanoparticle	miR-542-3p	Doxorubicin	Triple negative breast cancer (MDA-MB-231)	^107
Solid–lipid nanoparticle	Plasmid EGFP (model DNA)	Doxorubicin	NSCLC cells/tumor: A549	^108
Cationic core-shell nanoparticle	IL-12 pDNA or BCL-2 siRNA	Paclitaxel	4T1 mouse breast cancer model	^109
Heparin–Biotin/heparin/calcium carbonate/calcium phosphate	p53 pDNA	Doxorubicin	HeLa cells	^110
Calcium phosphate polymer hybrid nanoparticles	miR-221/222 Inhibitors	Paclitaxel	Triple-negative breast cancer (MDA-MB-231)	^111
Alginate/calcium carbonate hybrid nanoparticles	p53 pDNA	Doxorubicin	HeLa cells	^112

Kumar V, Mondal G, Slavik P, et al. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer. Mol Pharm 2015;12:1289–98.

 PubMed Web of Science ®Google Scholar

Chen Y, Zhu X, Zhang X, et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010;18:1650–6.

 PubMed Web of Science ®Google Scholar

Babu A, Wang Q, Muralidharan R, et al. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Mol Pharm 2014;11:2720–33.

 PubMed Web of Science ®Google Scholar

Ma X, Nguyen KT, Borah P, et al. Functional silica nanoparticles for redox-triggered drug/ssDNA co-delivery. Adv Healthc Mater 2012;1:690–7.

 PubMed Web of Science ®Google Scholar

Ren Y, Wang R, Gao L, et al. Sequential co-delivery of miR-21 inhibitor followed by burst release doxorubicin using NIR-responsive hollow gold nanoparticle to enhance anticancer efficacy. J Control Release 2016;28:74–86.

 Web of Science ®Google Scholar

Wang S, Zhang J, Wang Y, et al. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy. Nanomedicine 2016;12:411–20.

 PubMed Web of Science ®Google Scholar

Han Y, Zhang P, Chen Y, et al. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy. Int J Mol Med 2014;34:191–6.

 PubMed Web of Science ®Google Scholar

Wang Y, Gao S, Ye WH, et al. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006;5:791–6.

 PubMed Web of Science ®Google Scholar

Liang P, Wang CQ, Chen H, et al. Multi-functional heparin–biotin/heparin/calcium carbonate/calcium phosphate nanoparticles for targeted co-delivery of gene and drug. Polym Int 2015;64:647–53.

 Web of Science ®Google Scholar

Zhou Z, Kennella C, Lee JY, et al. Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors. Nanomedicine 2017;2:403–10.

 Web of Science ®Google Scholar

Zhao D, Liu CJ, Zhuo RX, et al. Alginate/CaCO3 hybrid nanoparticles for efficient codelivery of antitumor gene and drug. Mol Pharm 2012;9:2887–93.

 PubMed Web of Science ®Google Scholar